For healthcare professionals and partners

Tested in randomised trials

Enbioma’s dietary recommendations have been studied in randomised clinical trials, including a multicentre trial against the low-FODMAP diet with 12 months of published follow-up.

62.5%

Personalised diet

25 of 40 met the responder threshold at 12 months

34.5%

Low-FODMAP diet

10 of 29 met the responder threshold at 12 months

12-month follow-up of the low-FODMAP trial. Each dot is one participant assessed at 12 months (69 in total). The six-week primary endpoint did not differ between groups; the authors describe the 12-month findings as hypothesis-generating. Gut Microbes, 2026.

Four publications

Primary endpoint first. Each card gives the design, the numbers and the journal.

  • The American Journal of Gastroenterology

    Published 2024

    Compared with the low-FODMAP diet

    Multicentre randomised controlled trial in adults with irritable bowel syndrome: 149 randomised, 121 analysed at six weeks. Both groups improved; the change in IBS-SSS at six weeks, the primary endpoint, did not differ between the personalised diet and low-FODMAP groups.

  • Gut Microbes

    Published 2026

    12-month follow-up

    At 12 months, 62.5% of the personalised diet group (25/40) and 34.5% of the low-FODMAP group (10/29) met the responder threshold of a 50-point or greater reduction in IBS-SSS (p = 0.029). Open-label, outcome-assessor blinded; 69 participants assessed at 12 months. The authors describe these findings as hypothesis-generating.

  • Journal of Clinical Medicine

    Published 2022

    Functional constipation

    Single-centre randomised controlled trial: 50 randomised, 45 analysed, six weeks. Three or more complete bowel movements a week at week six: 21 of 25 (84%) in the personalised diet group and 8 of 20 (40%) in the control group, which received sodium picosulfate and conventional care (p = 0.003).

  • Biomedical Signal Processing and Control

    Published 2025

    Gut wellness score

    A deep-learning score developed on 4,015 gut microbiome profiles and tested on 785 external samples from seven public studies. AUC 93.4% in the paper’s cross-validation, benchmarked against GMWI2, an academic reference index. A retrospective modelling study, not a clinical outcome study or a diagnostic tool.

Two researchers reviewing printed study charts

Inside the trials

  • 149randomised in the multicentre trial against the low-FODMAP dietAJG 2024
  • 69participants assessed at 12 monthsGut Microbes 2026
  • 50randomised in the functional constipation trialJ Clin Med 2022

How to read it

  • Primary endpoint first

    In the low-FODMAP trial, the six-week primary endpoint did not differ between groups. The 12-month responder result comes from the follow-up of the same trial, with fewer participants, and the authors call it hypothesis-generating.

  • Active comparators

    The comparators were the low-FODMAP diet and, in the constipation trial, conventional care with sodium picosulfate. Results describe the personalised diet next to these approaches, not next to no intervention.

  • What was tested

    The trials tested the personalised dietary recommendations. They did not test the supplement suggestions or the report as a whole. The gut wellness score comes from a modelling study, not a clinical trial.

  • Who took part

    Adults with irritable bowel syndrome or functional constipation at hospital centres in Türkiye. The results may not apply to other groups.

What these studies cannot tell you

  • Open-label designs

    Participants knew which diet they followed; outcome assessors were blinded where stated.

  • Small samples

    69 of the 149 randomised participants were assessed at 12 months.

  • Single centre

    The constipation trial ran at one centre and was registered retrospectively.

  • Company involvement

    The studies were sponsored, funded or co-authored by the company, and they have not yet been independently replicated.

  • Sequencing method

    The clinical studies used 16S rRNA sequencing. Reports from shotgun data have not been studied in a clinical trial.

  • Modelling, not outcomes

    The wellness score paper is retrospective and does not test the score for individual follow-up.

Publications

  1. 01

    Tunali V, et al. A multicenter randomized controlled trial of microbiome-based artificial intelligence-assisted personalized diet vs low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet: a novel approach for the management of irritable bowel syndrome. The American Journal of Gastroenterology, 2024; 119(9): 1901-1912. doi:10.14309/ajg.0000000000002862

    The American Journal of Gastroenterology
  2. 02

    Tunali V, et al. Long-term microbiome and clinical effects of a microbiome-guided personalized diet versus low-FODMAP diet in irritable bowel syndrome: a 12-month follow-up randomized controlled trial. Gut Microbes, 2026; 18(1): 2719125. doi:10.1080/19490976.2026.2719125

    Gut Microbes
  3. 03

    Arslan NÇ, et al. Efficacy of AI-assisted personalized microbiome modulation by diet in functional constipation: a randomized controlled trial. Journal of Clinical Medicine, 2022; 11(22): 6612. doi:10.3390/jcm11226612

    Journal of Clinical Medicine
  4. 04

    Nalbantoğlu ÖU, Ermiş BH, Gündoğdu A. Deep learning-enhanced wellness scores: a population level study on gut microbiome profiling and health prediction. Biomedical Signal Processing and Control, 2025; 110: 108146. doi:10.1016/j.bspc.2025.108146

    Biomedical Signal Processing and Control

Enbioma is the only company in this landscape with published 12-month randomized follow-up.

The studies above were sponsored, funded or co-authored by Enbiosis, which develops and operates Enbioma. Company relationships are disclosed in each publication.